OP-ED: REINING IN DRUG INDUSTRY MIDDLEMEN
Rein in profiteering by drug-industry middlemen By David Balto The Federal Trade Commission recently requested public comments on the impact of drug-industry middlemen on drug affordability and access. Better known as pharmacy benefit manners, or PBMs, these are the unknown middlemen that manage prescription drug benefits for insurers and large employers. As part of their […]
